A detailed history of Kooman & Associates transactions in Abb Vie Inc. stock. As of the latest transaction made, Kooman & Associates holds 3,216 shares of ABBV stock, worth $647,059. This represents 0.23% of its overall portfolio holdings.

Number of Shares
3,216
Previous 3,230 0.43%
Holding current value
$647,059
Previous $554 Million 14.64%
% of portfolio
0.23%
Previous 0.22%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$163.84 - $199.33 $2,293 - $2,790
-14 Reduced 0.43%
3,216 $635 Million
Q2 2024

Aug 12, 2024

SELL
$154.79 - $180.76 $2,476 - $2,892
-16 Reduced 0.49%
3,230 $554 Million
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $21,096 - $24,037
-132 Reduced 3.91%
3,246 $591 Million
Q4 2023

Jan 29, 2024

BUY
$137.6 - $154.97 $4,953 - $5,578
36 Added 1.08%
3,378 $523 Million
Q3 2023

Nov 03, 2023

BUY
$133.59 - $154.65 $1,736 - $2,010
13 Added 0.39%
3,342 $498 Million
Q2 2023

Nov 03, 2023

SELL
$132.51 - $164.9 $27,429 - $34,134
-207 Reduced 5.85%
3,329 $448,000
Q2 2023

Jul 20, 2023

SELL
$132.51 - $164.9 $27,429 - $34,134
-207 Reduced 5.85%
3,329 $449 Million
Q1 2023

Nov 03, 2023

BUY
$144.61 - $166.54 $2,169 - $2,498
15 Added 0.43%
3,536 $564 Million
Q1 2023

Apr 21, 2023

BUY
$144.61 - $166.54 $2,169 - $2,498
15 Added 0.43%
3,536 $564 Million
Q4 2022

Nov 03, 2023

BUY
$138.31 - $165.87 $26,555 - $31,847
192 Added 5.77%
3,521 $569 Million
Q4 2022

Jan 24, 2023

BUY
$138.31 - $165.87 $486,989 - $584,028
3,521 New
3,521 $569 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $356B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Kooman & Associates Portfolio

Follow Kooman & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kooman & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Kooman & Associates with notifications on news.